Background: Heat shock protein 90 (Hsp90) is a molecular chaperone that is involved in signaling pathways for cell proliferation, survival, and cellular adaptation. Inhibitors of Hsp90 are being examined as cancer therapeutic agents, but the molecular mechanism of their anticancer activity is still unclear. We investigated Hsp90 as a therapeutic target for acute myeloid leukemia (AML) by use of the Hsp90 inhibitor shepherdin (a novel peptidyl antagonist of the interaction between Hsp90 and survivin, which is a regulator of cell proliferation and cell viability in cancer). 
Heat shock protein 90 (Hsp90) is a molecular chaperone ( 1 ) that participates in the quality control of protein folding. The mechanism of action of Hsp90 includes sequential ATPase cycles and the stepwise recruitment of cochaperones, including Hsp70, p50 cdc37 , p60 hop , and p23 ( 2 , 3 ) . In contrast to Hsp70, the molecular chaperone that controls folding of all newly synthesized proteins ( 4 ) , Hsp90 has a more restricted repertoire of client proteins (i.e., proteins that bind Hsp90 for proper maturation, consisting mostly of various kinases), and Hsp90 is typically involved in cell proliferation, cell survival, and cellular adaptation to unfavorable microenvironments ( 2 , 3 ) . The ability of Hsp90 to interact with multiple signaling networks is exploited by cancer cells, in which the expression of Hsp90 is increased ( 5 ) and the Hsp90 protein assumes a high-affi nity conformation with increased ATPase activity ( 6 ) . These characteristics indicate that Hsp90 may be a good target for cancer therapies. In fact, a small molecule inhibitor of Hsp90, the benzoquinone ansamycin antibiotic 17-allylamino-17-demethoxygeldanamycin (17-AAG), appears to act by suppressing the chaperone function of Hsp90, which causes the loss of expression of many client proteins. The safety evaluation of 17-AAG in four phase I studies ( 7 -10 ) was recently completed.
Acute myeloid leukemias (AMLs) ( 11 ) are a heterogeneous group of hematopoietic disorders for which novel therapeutic agents are needed. Although progress has been made in the management of acute promyelocytic leukemia, all other AML subtypes have dismal outcomes, especially if the patient is older ( 12 ) . Even recently developed molecular therapies that target critical AML signaling pathways have had a modest effect when administered without chemotherapy, and the standard of care for this disease has not changed for the last three decades ( 13 ) .
Hsp90 inhibition is being explored as a target for the treatment of AML, and 17-AAG has been shown to increase the activity of the chemotherapeutic agent cytarabine ( 14 ) , to act synergistically with histone deacetylase inhibitors ( 15 ) , and to increase the efficacy of small molecule inhibitors of FLT3, a client protein of Hsp90 that is frequently mutated in AML cells ( 15 ) . Another client protein of Hsp90 that appears to be a good therapeutic target for AML ( 16 ) is survivin ( 17 ) . Survivin is a member of the inhibitor of apoptosis gene family ( 18 ) and is overexpressed in AML cells from patients with primary ( 19 , 20 ) and myelodysplastic syndrome -derived ( 21 , 22 ) disease. Survivin is involved in the control of mitosis and the suppression of apoptosis or cell death ( 23 ) . The overexpression of survivin in AML cells may refl ect deregulated cytokine signaling ( 24 ) , especially that of granulocyte -macrophage colony-stimulating factor modulation of signal transduction and activation of transcription 3 ( 25 ) , and has been linked to unfavorable outcomes in patients with adult ( 26 ) or childhood ( 27 ) AML.
We have investigated shepherdin, a novel peptidomimetic inhibitor of the survivin -Hsp90 complex and of the function of Hsp90 ( 28 ) , as an anticancer agent in AML.
M ATERIALS AND M ETHODS

Cells and Cell Cultures
The following cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA): the human myeloblastic leukemia cell line HL-60, monocytic leukemia cell line THP-1, monoblast leukemia cell line U937, and chronic myelogenous leukemia in blast crisis cell line K562. The epithelial tumor cell lines, including the cervical carcinoma line HeLa and the breast adenocarcinoma line MCF-7, were also obtained from the ATCC. Cells were maintained in culture at 37 °C and in an atmosphere of 5% CO 2 and 95% air in RPMI 1640 medium containing 10 μ M HEPES, penicillin (100 U/mL), streptomycin (100 μ g/mL), and 10% fetal bovine serum.
Peripheral blood samples were obtained by venipuncture from normal healthy volunteers after written informed consent was obtained. Peripheral blood mononuclear cells (PBMCs) were isolated from these samples by Histopaque (Sigma-Aldrich, St. Louis, MO) gradient density centrifugation and maintained in culture in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics, as described above. For mitogenic stimulation, PBMCs were plated in a 96-well plate with each well containing 2 × 10 5 cells in 200 μ L of medium and incubated with phosphate-buffered saline (PBS) or phytohemagglutinin (5 μ g/mL; Sigma-Aldrich) at 37 °C in an atmosphere of 5% CO 2 and 95% air for up to 1 week. A blood sample was obtained, after written informed consent was provided and approval from an Institutional Review Board was given, from an 85-year-old patient diagnosed with secondary AML without maturation (M1 according to French -American -British classifi cation) with 82 000 white blood cells/mm 3 and 97% blasts. Patient-derived peripheral blasts were isolated as described above.
Peptide Synthesis
Peptides were synthesized by the W. M. Keck Biotechnology Research Center at Yale University School of Medicine or by Peptron, Inc. (Daejeon, South Korea). All peptides were synthesized by use of solid-phase chemistry, purifi ed to homogeneity (i.e., >98% pure) by reverse-phase high-pressure liquid chromatography, and assessed by mass spectrometry. The shepherdin peptide, named for its binding to the " shepherding " chaperone Hsp90, containing the survivin sequence between Lys-79 and Leu-87 or the corresponding scrambled peptide as a control were synthesized as described ( 28 ) . A novel shepherdin variant containing the 5-amino acid survivin sequence between Lys-79 and Gly-83 (KHSSG, termed shepherdin[79 -83]) was made cell permeable by adding the helix III from the cell-penetrating antennapedia homeodomain sequence (underlined) to its aminoterminal end: RQIKIWFQNRRMKWKK KHSSG-CONH 2 . The sequence of the cell-permeable control scrambled peptide was RQIKIWFQNRRMKWKK SGKHS-CONH 2 . In some experiments, peptides were synthesized with an amino-terminal biotin group for detection in cell culture and in vivo studies. All peptides were dissolved in water buffered with PBS at pH 7.4 immediately before use; working dilutions of the peptides were not stored.
Molecular Dynamics Simulations
For the simulation studies, the carboxyl and amino termini of shepherdin [79 -83] were considered to have no charge to avoid electrostatic artifacts from the attractions between free opposite charges at these termini. The side chain of Lys-79 was considered to be protonated, with a net charge of +1. The peptide was solvated with water in a periodic truncated octahedron that was large enough to contain the peptide and 0.9 nm of solvent on all sides. All solvent molecules within 0.15 nm of any peptide atom were removed. One Cl − counterion was added to ensure electroneutrality of the solution. The starting structure was totally extended to avoid biases in the conformational search. The simulation (production run) was 200 nanoseconds long. In all simulations, the temperature was maintained close to the intended value of 300 K by weak coupling to an external temperature bath with a coupling constant of 0.1 picosecond ( 29 ) . The peptide and the rest of the system were coupled separately to the temperature bath ( 29 ) . The GROMOS96 force fi eld ( 30 ) , the simple point-charge water model ( 31 ) , the LINCS (linear constraint solver) algorithm ( 32 ) , and the Settle (an analytical version of the SHAKE and RATTLE algorithms) algorithm ( 33 ) were used. The density of the system was adjusted as described ( 29 ) . All molecular dynamics simulation analyses of trajectories were performed with the GROMACS software package ( 34 ) . Conformational cluster analysis of the 200-nanosecond trajectory for shepherdin[79 -83] was performed as described ( 35 ) .
The representative structure of the most populated cluster of shepherdin [79 -83] without the antennapedia cell-penetrating sequence, corresponding to the most visited structures in the molecular dynamics simulation, was used for docking experiments on the amino-terminal domain of Hsp90. We used the Autodock program ( 36 ) for these experiments. The crystal structure of Hsp90 was taken from the protein data bank (code 1YET. pdb). The original x-ray structure contains the ligand geldanamycin, which was removed from the active site to yield the apoopen form of Hsp90 ( 37 ) . The docking procedure was carried out as described ( 28 ) . The results of the clustering procedure and subsequent molecular dynamics refi nements were classifi ed by a two-step procedure. First, the docked conformations of the ligand peptides were listed in increasing energy order. The structure of the complex that corresponded to the global minimum energy was used as the starting point of the fi rst refi nement molecular dynamics run. Second, the ligand conformation with the lowest energy was used as a reference, and all conformations with a center of mass to center of mass distance of less than 3 Å from the reference were taken to belong to the fi rst class. After a ligand was assigned to a class, it was not used again for other classes. The process was then repeated for all hitherto unclassifi ed conformations until all conformations were put in a class. The representative structure of the most populated class was then used for the second molecular dynamics refi nement run.
The two molecular dynamics runs of the complexes obtained after the Autodock runs were each 70 nanoseconds long.
Peptide Binding and Competition Experiments
Binding of shepherdin variants to Hsp90 was assessed by use of the enzyme-linked immunosorbent assay (ELISA), as described ( 28 ) . Briefl y, plastic microtiter wells were coated with increasing concentrations (0.09 -200 μ g/mL) of shepherdin peptides or their scrambled peptides, and unbound sites were blocked with 3% gelatin. The recombinant Hsp90 N-domain region (Hsp90 residues 1 -272, 1 μ g/mL), which contains the binding site for shepherdin, was produced in BL-21 Escherichia coli as a glutathione S -transferase fusion protein, further isolated from glutathione S -transferase by thrombin cleavage ( 28 ) , and added to peptide-coated plates. After a 2-hour incubation at 22 °C, protein binding under the various conditions tested was detected with an antibody against Hsp90 and visualized by a peroxidaseconjugated secondary species-specifi c antibody. The reaction was quantifi ed by absorbance at 405 nm. Alternatively, the recombinant Hsp90 N-domain protein (10 μ g/mL) was immobilized on plastic microtiter wells and incubated with increasing concentrations of shepherdin variants or their scrambled peptides (0.09 -200 μ g/mL) for 2 hours at 22 °C. After addition of recombinant survivin (1 μ g/mL), binding of survivin to shepherdin peptide-treated Hsp90 was determined by ELISA, as described above ( 28 ) .
To assess the ability of shepherdin to displace ATP from the Hsp90 -ATP complexes ( 38 ) Samples were further incubated with 50 μ L of γ -phosphate linked ATP-Sepharose (Boca Scientifi c) for 2 hours at 4 °C, and after washes in molybdate buffer, the Sepharose-bound material was eluted in 5% sodium dodecyl sulfate (SDS) and examined by western blot analysis ( 28 ) .
Fluorescence Microscopy
HL-60 cells or PBMCs were plated onto poly-L -lysine -coated coverslips at 1 × 10 6 cells per mL of medium and incubated with cell-permeable biotinylated shepherdin peptides or their scrambled sequences at a fi nal concentration of 50 μ M. After a 1-hour incubation, cells were washed in PBS (pH 7.4), fi xed in methanol overnight at − 20 °C, and stained with a 1:1000 dilution of streptavidin -Texas red (Amersham Biosciences, Buckinghamshire, UK; to bind to the biotin attached to the cell-permeable shepherdin peptides) in 300 μ L of PBS (pH 7.4) containing 0.1% Triton X-100. Intracellular penetration of the various peptides was visualized by fl uorescence microscopy.
Western Blot Analysis
We incubated 1 × 10 6 cells with cell-permeable shepherdin peptides, their scrambled sequences, or 17-AAG (Alexis Biochemicals) as indicated. Cells were collected by centrifugation (2095 g for 10 minutes at 4 °C) and washed in PBS (pH 7.4). Cell extracts were prepared by incubating cells in 20 mM Tris-HCl (pH 7.2), 0.5% deoxycholic acid, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, and 1 mM EDTA for 1 -2 hours at 0 °C. Supernatants were collected by centrifugation (15 700 g for 30 minutes at 4 °C), and protein-normalized supernatants were separated by SDS -polyacrylamide gel electrophoresis on 12% gels. After transfer of the protein bands to polyvinylidene difl uoride membranes (Immobilon P Transfer Membrane; Millipore Corp., Billerica, MA), nonspecifi c binding sites on the blots were blocked in 5% skim milk, and the blots were incubated with various primary antibodies against survivin, cytochrome c , Akt, cyclin-dependent kinase 6 (CDK-6), Hsp70, Hsp90, or β -actin for 16 hours. Protein bands with bound antibodies were detected with horseradish peroxidase -conjugated species-specifi c secondary antibodies and visualized by chemiluminescence (Amersham Biosciences).
Cell Viability, Apoptosis, and Analysis of Mitochondrial Membrane Potential
HL-60, K562, THP-1, or U937 AML cell lines, patientderived blasts, or unstimulated or phytohemagglutinin-stimulated PBMCs (each at 1 × 10 6 cells per mL) were incubated in 96-well plates with cell-permeable shepherdin peptides or their corresponding scrambled peptides for 30 minutes at 37 °C. At the end of the incubation, cultures were analyzed in triplicate for cell viability with a 3-( 4 , 5 -dimethylthyazoyl-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay at an absorbance of 405 nm, as described ( 28 ) . Alternatively, 1 × 10 6 AML cells per 1 mL were treated with shepherdin peptides or their corres ponding scrambled peptides for 30 minutes at 37 °C. Cells were harvested and simultaneously analyzed for caspase activity by measuring the level of DEVDase activity (Asp-Glu-ValAsp cleavage activity; green channel) and plasma membrane integrity by measuring the level of propidium iodide (red channel) (CaspaTag; Intergen, Burlington, MA) by multiparametric fl ow cytometry. In other experiments, HL-60 cells were labeled for 10 minutes in the dark with the mitochondrial membrane potential -sensitive fl uorescent dye JC-1 (10 μ g/mL of PBS; Molecular Probes). After three washes in PBS (pH 7.2), samples were incubated with shepherdin[79 -83] or control scrambled peptide from 2 to 30 minutes and analyzed by fl ow cytometry to monitor changes in the red/green (Fl-2/Fl-1) fl uorescence ratio to obtain the index of mitochondrial membrane depolarization. JC-1 -stained cultures treated with carboxyl cyanide 3-cholorphenyl hydrazone were used as positive control for these experiments.
Xenograft Tumor Model
All experiments involving animals were approved by an institutional animal care and use committee. We injected 1 × 10 7 HL-60 cells suspended in 200 μ L of sterile PBS into both fl anks of 6-to 8-week-old CB17 SCID/beige mice (Taconic Farms, Germantown, NY) and allowed the injected cells to grow as palpable tumors for 10 days. When tumors reached a volume of 100 -150 mm 3 , animals were randomly assigned to one of the two groups (two tumors per mouse and three mice per group) that received saline or shepherdin[79 -83] at 50 mg/kg for 11 consecutive days by intraperitoneal injection (200 μ L per injection). Tumor measurements were taken daily with a caliper, and tumor volume was calculated with the formula ([length in millimeters] × [width in millimeters] 2 )/2. At the end of the experiment, the various AML tumors, liver, kidneys, and lungs were harvested from both groups of animals. Tissue samples were fi xed in formalin, embedded in paraffi n, and sectioned. Sections were placed on slides and stained with hematoxylin -eosin or with antibodies against survivin (NOVUS Biologicals, Littleton, CO) or Akt (Cell Signaling Technology, Beverly, MA). Antibody binding was detected by immunohistochemistry and peroxidase-conjugated species-specifi c secondary antibodies and visualized with 3,3-diaminobenzidine as a chromophore. Sections were reviewed by the University of Massachusetts Memorial Cancer Center Veterinary Pathology Core. Images were captured through an Olympus microscope with an on-line chargecoupled device camera.
Statistical Analysis
All data were analyzed with two-sided unpaired t tests in the GraphPad software package for Windows (Prism version 4.0). A P value of .05 was considered as statistically signifi cant. Values are expressed as means of triplicate or duplicate experiments. For analysis of xenograft tumor growth, data were corrected to account for within-animal correlations by averaging the withinanimal volumes and calculating a best estimate of the tumor volume for each mouse. The mean and SEM were then calculated with mice as the data units. All statistical tests were two-sided.
R ESULTS
Identifi cation of an Optimized Variant of Shepherdin
Because the shepherdin residues between Lys-79 and Gly-83 had previously been identifi ed as being essential for Hsp90 binding ( 28 ) , we synthesized a new fi ve-residue peptide containing the survivin sequence between residues 79 and 83, KHSSG (named shepherdin [79 -83] ( Fig. 1, A ) . Shepherdin [79 -87] or shepherdin[79 -83], but not their corresponding scrambled peptides, also inhib ited the binding of recombinant survivin to Hsp90 with similar affi nities and in a concentration-dependent manner ( Fig. 1, B ) .
We next studied the predicted structure of the shepherdin[79 -83] -Hsp90 complex by molecular dynamics simulations. In these simulations, shepherdin[79 -83] did not have a preferred ordered secondary structure, and so the hydrophilic side chains and the backbone carboxyl and amino groups tended to maximize their interactions with the surrounding water solvent. Cluster analysis of the 200-nanosecond simulations determined that the main conformational family of shepherdin[79 -83] was characterized by a slight bend geometry involving residues His-80, Ser-81, and Ser-82. Docking experiments that used shepherdin with this geometry predicted that shepherdin [79 -83] bound to the ATP pocket of Hsp90 ( Fig. 1, C and D ) . Two different orientations of shepherdin[79 -83] were observed: one that corresponded to the global free-energy minimum structure of the shepherdin -Hsp90 complex and one that represented the most frequently obtained structure after statistical clustering of all the structures studied during the Autodock simulations. The sites of contact between Hsp90 and shepherdin[79 -83] in either confi guration overlapped ( Fig. 1, C and D ) . In the global free-energy minimum confi guration ( Fig. 1, C ( Fig. 1, D ) , His-80 in shepherdin[79 -83] formed a hydrophobic interaction with Ile-96 in Hsp90 but was also involved in a new hydrogen bonding interaction with the side chain of Asp-54 in Hsp90; Ser-81 interacted with Asp-93 and Asn-106 in Hsp90, and Ser-82 interacted with Asn-106 and Asp-102 in Hsp90. Consistent with these molecular dynamics predictions, shepherdin[79 -83] effi ciently displaced ATP binding from the N-domain of recombinant Hsp90, whereas the scrambled peptide was ineffective ( Fig. 1, E ) .
Anti-AML Activity of Shepherdin[79 -83]
Endogenous survivin was highly expressed by AML cell lines, including the myeloblastic cell line HL-60, the acute monocytic cell line THP-1, the monoblast leukemia cell line U937, and K562, the cell line from a blast transformation of chronic myelogenous leukemia ( Fig. 2, A ) of all AML cell lines ( Fig. 2, C ) . In contrast, cell-permeable scrambled peptides did not essentially decrease AML cell viability in 30 minutes ( Fig. 2, C ) . In addition, comparable concentrations of shepherdin [79 -87] or shepherdin[79 -83], but not their scrambled peptides, killed HeLa or MCF-7 cells, which are derived from epithelial tumor types, with equal activity ( Fig. 2, D ) .
Mechanisms of Shepherdin[79 -83] Anti-AML Activity
The speed of shepherdin-mediated cell killing was further investigated. A 30-minute exposure of various AML cell types to shepherdin[79 -83] (75 μ M) was suffi cient to induce high levels of caspase activity and the loss of plasma membrane integrity in all cells treated, as demonstrated by multiparametric fl ow cytometry ( Fig. 3, A ) . In contrast, the corresponding cellpermeable scrambled peptide did not induce caspase activity or disrupt the integrity of the plasma membrane, as compared with untreated cultures ( Fig. 3, A ) . Under these experimental conditions, treatment of HL-60 cells with shepherdin [79 -83] resulted in the rapid discharge of mitochondrial cytochrome c in the cytosol, in a reaction that was completed within 10 minutes after peptide addition, as measured by western blot analysis ( Fig. 3, B ) . To further characterize the speed at which shepherdin induced mitochondrial dysfunction, control or treated HL-60 cells were evaluated for changes in the membrane potential of mitochondria. A 2-minute exposure of HL-60 cells to shepherdin [79 -83] resulted in collapse of mitochondrial membrane potential, as demonstrated by JC-1 staining and fl ow cytometry, whereas such an exposure to the control scrambled peptide had no effect ( Fig. 3, C ) .
We next investigated whether shepherdin treatment altered the expression levels of Hsp90 client proteins. For these experiments, we used a suboptimal concentration (20 ( Fig. 3, D ) . In time-course experiments, treatment of HL-60 cells with shepherdin[79 -83], but not scrambled peptide, induced loss of Akt expression as early as 30 minutes after treatment ( Fig.  3, E ) ; the loss of Akt expression may further contribute to the rapid kinetics of cell death induced by shepherdin, given the broad survival functions of this kinase.
Functional Diversity Between Shepherdin and 17-AAG
Because of the unique structure of the shepherdin -Hsp90 complex and because of the speed with which shepherdin can kill AML cells, we next investigated whether the anticancer mechanisms used by shepherdin and by 17-AAG (a clinically available prototype Hsp90 inhibitor) differed. Treatment of HL-60 cells with 17-AAG resulted in the time-dependent increased expression of Hsp70, as shown by western blot analysis ( Fig. 4, A ) . peptides did not alter the expression of Hsp70 ( Fig. 4, B ) . Consistent with the data presented above, a 30-minute exposure of HL-60 cells to shepherdin[79 -83], but not its corresponding scrambled peptide, was suffi cient to produce concentrationdependent loss of cell viability in the entire cell population, as determined by a MTT assay ( Fig. 4, C ) . In contrast, treatment with 17-AAG did not substantially affect HL-60 cell viability, even after 24 hours of treatment ( Fig. 4, C ) . However, a 48-hour exposure of HL-60 cells to 17-AAG resulted in a 60% -65% decrease in cell viability ( Fig. 4, C ) , which is consistent with its anticancer activity ( 39 ) .
Selectivity of Shepherdin Anti-AML Activity
Mitogenic stimulation of PBMCs with phytohemagglutinin resulted in cell cycle progression and the increased expression of survivin; the reaction peaked 3 days after stimulation ( Fig. 5, A ) , as previously observed ( 40 ) . Shepherdin[79 -87], shepherdin[79 -83], or their scrambled sequences effi ciently accumulated intracellularly in phytohemagglutinin-stimulated PBMCs, as assessed by fl uorescence microscopy ( Fig. 5, B ) . Treatment of phytohemagglutinin-stimulated PBMCs with shepherdin[79 -87] or shepherdin [79 -83] at concentrations suffi cient to induce complete AML cell killing did not decrease the viability of PBMCs, as compared with control cultures treated with scrambled peptides ( Fig. 5, C ) . In contrast, shepherdin[79 -83] induced extensive killing of patient-derived AML peripheral blasts within 30 minutes of treatment, whereas a scrambled peptide was ineffective ( Fig. 5, D ) .
Anti-AML Activity of Shepherdin[79 -83] In Vivo
We injected HL-60 cells subcutaneously into both fl anks of immunocompromised SCID/beige mice to give rise to exponentially growing tumors. When tumors reached a volume of 100 -150 mm 3 , animals (three animals per group per experiment) were used in the following experiments. Within 1 hour after treatment of tumor-bearing mice, systemically administered shepherdin[79 -83] had accumulated within the tumor mass, as detected by immunofl uorescence microscopy, but tumors of saline-treated control tumor-bearing animals showed no immunofl uorescence ( Fig. 6, A ) . Treatment of tumor-bearing animals with shepherdin[79 -83] (50 mg/kg per day, intraperitoneally) for 11 days completely suppressed tumor growth (mean of control group = 1698 mm 3 , mean of treated group = 232 mm 3 ; difference = 1466 mm 3 , 95% confi dence interval = 505.8 to 2426; P = .008), whereas treatment with saline for 11 days had no inhibitory effect on tumor growth ( Fig. 6, B ) . Immunohistochemical analysis of AML tumors revealed that shepherdin treatment induced a high level of apoptosis in tumor cells, as determined by nuclear fragmentation and the loss of expression of Hsp90 client proteins survivin and Akt ( Fig. 6, C ) , which is consistent with Hsp90 inhibition in vivo. In contrast, saline-treated AML tumors contained many mitotic cells and showed the diffuse expression of survivin and Akt ( Fig. 6, C ) . In addition, examination of kidney, liver, and lung tissue collected from shepherdin-treated animals at the end of treatment was unremarkable, compared with the saline group, indicating that prolonged shepherdin administration did not induce organ toxicity ( Fig. 6, D ) .
D ISCUSSION
In this study, shepherdin[79 -83], a novel peptidyl antagonist of the survivin -Hsp90 interaction, was shown to act as an inhibitor of Hsp90, with strong and selective anti-AML activity both in vitro and in xenograft tumors. We also found unexpected molecular and functional diversity between the Hsp90 inhibitors shepherdin[79 -83] and 17-AAG in their binding to Hsp90, their speed of tumor cell killing, and their ability to quickly disrupt mitochondrial function.
Our results reinforce previous observations that shepherdin acts as a genuine Hsp90 inhibitor ( 28 ) , in that it binds to the ATP pocket of Hsp90, it can displace Hsp90-bound ATP, and it destabilizes multiple Hsp90 client proteins in vitro and in vivo. Third, shepherdin appeared to have at least two anticancer mechanisms. One mechanism induced the loss of expression of multiple Hsp90 client proteins involved in cell proliferation and cell survival, probably through their destabilization and proteasome-dependent destruction, which is reminiscent of the mechanism used by 17-AAG. The other anticancer mechanism used by shepherdin included the fast disruption of mitochondrial function, involving dissipation of the mitochondrial membrane potential within 2 minutes of treatment and release of mitochondrial cytochrome c within 10 minutes. These events were followed within 30 minutes by increased activity of the effector caspases ( 42 , 43 ) . Although 17-AAG also disrupts mitochondrial functions, more time is required, possibly because of the delayed loss of Hsp90 client protein(s) such as Akt ( 39 ) , which ultimately results in mitochondrial dysfunction.
Fourth, shepherdin treatment did not alter Hsp70 levels in AML cells, unlike 17-AAG treatment, which consistently increases the cell death by shepherdin in cancer cells, may indicate that shepherdin can be administered for a long time in vivo without Hsp70-associated side effects. A limitation of this study is that the molecular differences in the mechanisms of action for shepherdin and 17-AAG have not been fully elucidated. Previous experiments validated the specifi city of shepherdin for Hsp90 and ruled out its interaction with Hsp70 ( 28 ) . The unique properties of shepherdin may refl ect its structurally distinctive binding to the ATP pocket of Hsp90, which might affect the recruitment of cochaperones, such as p50 cdc37 ( 49 ) or the stability or maturation of client proteins that are not affected by treatment with 17-AAG. Because of the rapid onset of shepherdin-induced disruption of mitochondrial permeability, it is also possible that shepherdin may directly target a specialized subcellular pool of Hsp90 associated with mitochondrial homeostasis. This mechanism is consistent with a role for Hsp90 in the importation of proteins by mitochondria through the Tom70 receptor ( 50 ) and the ability of an Hsp90 -Hsp70 complex to counteract discharge of cathepsin G by lysosomes; cathepsin G, in turn, can mediate the mitochondrial permeability transition ( 48 ) .
These data support the development of shepherdin or its advanced derivatives for use in novel anticancer strategies. When tested in a xenograft AML model, shepherdin had strong singleagent activity that suppressed tumor growth, induced apoptosis in the tumor, and decreased the expression of Hsp90 client proteins (e.g., survivin and Akt); these results indicate that shepherdin functions as an Hsp90 inhibitor in vivo. Similar to earlier results with shepherdin[79 -87] in solid tumors ( 28 ) , prolonged systemic administration of shepherdin[79 -83] was well tolerated by mice. Preliminary analyses of toxicity and histologic examination of the kidneys, lungs, and liver were unremarkable, which is in keeping with the safety of shepherdin for normal cells, including hematopoietic progenitors ( 28 ) or actively proliferating, survivin-expressing PBMCs ( Fig. 5 ) . This degree of selectivity may refl ect the higher affi nity with which Hsp90 binds ATPase pocket antagonists in tumor cells as opposed to normal tissues ( 6 ) , a result that has also been previously validated for shepherdin in affi nity chromatography experiments ( 28 ) .
In summary, shepherdin belongs to a novel class of Hsp90 inhibitors whose members have a dual mechanism of anticancer activity involving the rapid disruption of mitochondrial function and decreased expression of Hsp90 client proteins, such as survivin, Akt, and CDK-6. The combined molecular properties of shepherdin, its selectivity for transformed cells, and its safety in mice indicate that shepherdin may be a good lead prodrug for the development of therapies for AML and other epithelial malignancies.
